Sun Pharmaceutical Industries Limited has received a communication from the US FDA indicating the inspection classification of Halol (Gujarat) facility as "Official Action Indicated" (OAI). The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved. The Company continues to manufacture and distribute existing products for the US market, thereby not likely to have any material adverse impact on current business from the facility.
Sun Pharma continues to cooperate with the US FDA and will undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the Company's remedial action.
Sun Pharma remains committed to being GMP compliant and in supplying high-quality products to its customers and patients globally.
Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 913.40 as compared to the previous close of Rs. 920.00. The total number of shares traded during the day was 27792 in over 1299 trades.
The stock hit an intraday high of Rs. 924.90 and intraday low of 907.50. The net turnover during the day was Rs. 25364014.00.